Creso Pharma seals $2.5M cannabidiol distribution agreement
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited’s (ASX: CPH; FRA: 1X8) strong performance over the last three months - during which time its share price has surged more than 500% - may be set to continue with the negotiation of a comprehensive distribution agreement with a leading nutritional supplements company, Route2 Pharm Pvt Ltd (Route2).
The three year agreement is for minimum order quantities for the first contractual year of up to CHF1.71 million (AU$2.48 million) across the CannaQix 10, Cannaqix 50 and CannaDOL product lines, pro-rata subject to timing of product registrations.
Under the terms of theAgreement , Route 2 has exclusivity rights over Creso's cannaQIX® and cannaDOL product lines, subject to Route 2 achieving minimum order quantities for each product line in the first contractual year, being 1 January to 31 December.
First Contractual Year minimum order quantities are as follows:
This agreement will involve the importation, marketing and distribution of its innovative hemp-derived therapeutic products into Pakistan and other countries including the Philippines, further expanding Creso Pharma’s sales capacity.
Route2 is a subsidiary company of Route2Health (www.route2health.net).
Route2Health has over 30 years of pharmaceutical sciences experience and produces and distributes world-class herbal remedies and dietary supplements.
The group is based in Pakistan and has state-of-the-art manufacturing facilities and partnerships with other industry participants.
Another opportunity as regulatory changes open up new markets
The agreement follows a landmark decision made by the Pakistan government in September 2020, which will allow the country to enter into the billion-dollar cannabidiol (CBD) market, through a focus on cultivating cannabis and hemp for therapeutic products.
Route2 has a strategic association with Highnoon Laboratories Limited (PSX: HINOON), one of Pakistan’s most successful and progressive pharmaceutical companies.
As indicated below, shares in Highnoon have performed strongly since markets rebounded in March last year, increasing some 70%.
Under the agreement, both parties have agreed, subject to further regulatory approvals, to leverage their combined international reach to distribute and sell Creso’s products into additional markets.
Creso Pharma said that these include Afghanistan, Azerbaijan, Bangladesh, Cambodia, Georgia, the Maldives, Myanmar, the Philippines, Tajikistan, Turkmenistan, Uzbekistan, and Vietnam.
This considerably broadens the company’s international footprint and unlocks a number of large market opportunities.
Targeting a population of 200 million in Pakistan
Pakistan has a population of over 200 million and a wide range of unmet needs that can be addressed by Creso’s targeted portfolio of products that includes cannabis and hemp-derived products, focusing on four key areas including therapeutics, nutraceuticals, animal health, and cosmetics.
Creso Pharma currently has a portfolio of 13 products, eight of which have been commercialised and are generating revenues, as well as a strong product development pipeline.
Discussing Creso Pharma’s extensive market opportunities, and more specifically the agreement with Route2Health, non-executive chairman Adam Blumenthal said, "This agreement takes Creso into markets with a combined population of over 750 million people.
"Our mission is to deliver access to affordable, high quality, broad-spectrum, GMP products for the betterment of people’s lives everywhere.
"We’re delighted to conclude this important partnership through which we hope to provide the opportunity for millions of people to have access to our innovative products.”
Managing director of Route2 Shahnawaz Baig discussed the groups’ shared goals saying, “We are very excited to progress this partnership with leading global cannabis company Creso Pharma.
"There exists a vast amount of real-world and strong clinical evidence that supports the safety and efficacy of hemp-based therapeutic products.
"The basis for this partnership is a shared commitment of bringing affordable, high quality products to market that improve people’s lives.
"We intend to fully leverage the financial and marketing strength of our group to deliver on this mission.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
